IPP Bureau
Thermo Fisher Scientific expands its capabilities in France
By IPP Bureau - April 10, 2023
Bourgoin early development hub broadens offerings for oral solid dose formulations
Virpax reports on progress of Envelta
By IPP Bureau - April 10, 2023
Envelta is the company’s non-opioid pain product candidate for acute and chronic pain
Newly patented bone marrow biopsy device to bolster bone cancer treatment in India, says GlobalData
By IPP Bureau - April 10, 2023
It provides doctors with three indicators: identification of the bone, confirmation of device insertion into the bone, and notification in case of perforation through the opposite end of the bone
AIIA to host a Working Group of C20 on Integrated Holistic Health
By IPP Bureau - April 08, 2023
The C20 is an engagement group of the G20 that focuses on Civil issues and looks to promote sustainable growth and financial stability.
Emcure Pharmaceuticals bags Merit Award at HIV Congress 2023
By IPP Bureau - April 08, 2023
The Award acknowledges Emcure's contribution in the field of HIV/AIDS to improve the quality of life of people living with HIV/AIDS.
Cognizant, Microsoft collaborate to bring cloud-based solutions to the healthcare market
By IPP Bureau - April 08, 2023
Microsoft Cloud for Healthcare and Cognizant’s TriZetto healthcare products aim to enhance transparency for consumers and increase interoperability for providers and payers
Tillotts Pharma announces the launch of Octasa 1600 mg Tablets in Canada
By IPP Bureau - April 08, 2023
The introduction of Octasa 1600 mg to the Canadian market is expected to increase the options for UC patients managed with mesalazine.
Inflation and declining FDA drug approvals will pose challenges for pharma contract manufacturers in 2023, says GlobalData
By IPP Bureau - April 08, 2023
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Todaro Robotics completes 2+ years partnership with Abwiz Bio
By IPP Bureau - April 07, 2023
The milestone of operating continuously a very complex system for over two years has demonstrated the effectiveness of integrated laboratory automation solutions
mRNA-4157/V940in combination with Keytruda receives PRIME scheme designation from EMA
By IPP Bureau - April 07, 2023
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
Zydus receives final approval from the USFDA for Carbidopa and Levodopa Tablets
By IPP Bureau - April 07, 2023
Carbidopa and Levodopa is used to treat symptoms of Parkinson's disease or Parkinson-like symptoms
Zydus receives final approval from the USFDA for Acetazolamide Tablets
By IPP Bureau - April 07, 2023
Acetazolamide is used to treat glaucoma
Apitoria Pharma appoints Dr. Sanjay Chaturvedi as CEO
By IPP Bureau - April 06, 2023
Venkat Nageswar Chalasani has been appointed as an Independent Director of Apitoria Pharma with effect from April 4, 2023
Approx 800 million Indians do not have health coverage, says Expert
By IPP Bureau - April 06, 2023
Government hospitals like AIIMS, KGMC & many more as per day OPD patients are 18-25 thousand
